{
    "clinical_study": {
        "@rank": "6625", 
        "arm_group": [
            {
                "arm_group_label": "Standard Care + NAC infusion", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Standard Care", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Patient presenting with upper GI bleed in ILBS (Institute of Liver and Biliary Sciences)\n      emergency admitted to ICU (Intensive Care Unit) or shifted from ward to ICU (Intensive Care\n      Unit) in view of upper GI bleed randomized to two groups\n\n      GROUP A  :  70  Patients  will receive standard care   +  NAC infusion for 72 hours\n\n      GROUP B :   70 Patients will receive standard care only\n\n      NAC will be given at following rate :\n\n      Initial loading of 150 mg/kg/hr over 1 hour Followed by 12.5mg/kg/hr for 4 hrs Then\n      continuous infusion of 6.25 mg/kg for the remaining 67 hrs"
        }, 
        "brief_title": "To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Hepatitis.", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Ischemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 and < 75\n\n          -  Cirrhotics with UGIE (Upper Gastrointestinal Endoscopy ) within last 24 hours.\n\n        Exclusion Criteria:\n\n          -  Non cirrhotic\n\n          -  Hepatocellular carcinoma\n\n          -  Advanced cardiopulmonary disease\n\n          -  Pregnancy\n\n          -  Portal vein Thrombosis\n\n          -  Extrahepatic malignancy\n\n          -  Patient on anticoagulation therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015403", 
            "org_study_id": "ILBS-IH-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Care", 
                "intervention_name": "Standard Care with NAC (N-ACETYLCYSTEINE)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard Care + NAC infusion", 
                "intervention_name": "Standard Care", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "email": "awinsinha81@gmail.com", 
                "last_name": "Dr Awinash Kumar, MD", 
                "phone": "011-46300000"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of Liver & Biliary Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "TO COMPARE THE EFFICACY OF N -ACETYLCYSTEINE AND STANDARD THERAPY VERSUS STANDARD THERAPY IN THE PREVENTION OF ISCHEMIC HEPATITIS AND SURVIVAL POST UPPER GI BLEED", 
        "overall_contact": {
            "email": "awinsinha81@gmail.com", 
            "last_name": "Dr Awinash Kumar, MD", 
            "phone": "011-46300000"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Prevention of Hypoxic hepatitis.", 
            "safety_issue": "No", 
            "time_frame": "1 Year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Mortality", 
            "safety_issue": "Yes", 
            "time_frame": "1 Year"
        }, 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}